AYTU Biopharma (AYTU) grants CBO 15,000 restricted stock shares

Rhea-AI Filing Summary

Disbrow Jarrett reported acquisition or exercise transactions in this Form 4 filing.

Jarrett Disbrow, Chief Business Officer of AYTU Biopharma, reported a grant of 15,000 shares of common stock as restricted stock. The award increases his direct holdings to 76,568 shares and vests over time starting July 28, 2027 in quarterly installments.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Disbrow Jarrett

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	15,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 76,568 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

Key Figures

Restricted stock grant: 15,000 shares Holdings after grant: 76,568 shares Initial vesting date: July 28, 2027 +1 more

4 metrics

Restricted stock grant 15,000 shares Grant of AYTU common stock reported on July 28, 2026

Holdings after grant 76,568 shares Direct ownership following the reported restricted stock grant

Initial vesting date July 28, 2027 Date when 1/3 of the restricted stock grant vests

Quarterly vesting start October 28, 2027 Start of eight equal quarterly installments for remaining restricted shares

Key Terms

restricted stock, vesting, quarterly installments

3 terms

restricted stock financial

"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

vesting financial

"restricted stock, which vest as follows: 1/3 on July 28, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

quarterly installments financial

"remaining restricted stock vesting in 8 equal quarterly installments"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:34 PM Accepted by SEC EDGAR 07/30/2026 - 04:33 PM Learn about SEC filing dates

FAQ

What insider transaction did AYTU’s Jarrett Disbrow report on this Form 4?

Jarrett Disbrow reported a grant of 15,000 shares of AYTU common stock as restricted stock. Following this grant, his direct holdings total 76,568 shares, according to the Form 4 filing.

How many AYTU shares does Jarrett Disbrow hold after this reported grant?

After the reported restricted stock grant, Jarrett Disbrow directly holds 76,568 AYTU shares. This total reflects the addition of 15,000 restricted shares granted on July 28, 2026.

What is the vesting schedule for Jarrett Disbrow’s 15,000 AYTU restricted shares?

The 15,000 restricted shares vest with 1/3 on July 28, 2027, and the remaining 2/3 in eight equal quarterly installments beginning October 28, 2027, as described in the footnote to the transaction.

Was Jarrett Disbrow’s AYTU stock grant made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote indicating a trading plan. The reported transaction is a grant of restricted stock, not an open-market trade.

What type of security did AYTU’s Chief Business Officer receive in this Form 4?

Jarrett Disbrow received restricted stock in the form of 15,000 shares of AYTU common stock. These shares vest over time beginning in 2027, rather than being fully vested at the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Disbrow Jarrett

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		15,000(1)	A	$0	76,568	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

	/s/ Ryan J. Selhorn as attorney-in-fact for Jarrett T. Disbrow	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)